New drug duo tested for Tough-to-Treat cervical cancer
NCT ID NCT06266338
Summary
This study is testing whether combining two existing drugs, pembrolizumab and lenvatinib, can help slow tumor growth in women whose cervical cancer has spread or returned after prior treatment. The trial will enroll about 30 participants to see how well the combination works and how safe it is. This is for patients who have already tried other treatments, including certain immunotherapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.